US5614492A
(en)
*
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
US7138486B2
(en)
*
|
1986-05-05 |
2006-11-21 |
The General Hospital Corporation |
Insulinotropic hormone derivatives and uses thereof
|
US6849708B1
(en)
|
1986-05-05 |
2005-02-01 |
The General Hospital Corporation |
Insulinotropic hormone and uses thereof
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
CA2262647C
(en)
|
1996-08-08 |
2007-12-04 |
Amylin Pharmaceuticals, Inc. |
Methods for regulating gastrointestinal motility
|
ES2425559T5
(es)
*
|
1997-01-07 |
2018-02-02 |
Amylin Pharmaceuticals, Llc |
Composiciones farmacéuticas que comprenden las exendinas y los agonistas de las mismas
|
US5846937A
(en)
*
|
1997-03-03 |
1998-12-08 |
1149336 Ontario Inc. |
Method of using exendin and GLP-1 to affect the central nervous system
|
US7157555B1
(en)
*
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
JP2003522721A
(ja)
|
1997-11-14 |
2003-07-29 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
新規なエキセンジンアゴニスト化合物
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
KR100637433B1
(ko)
*
|
2004-05-24 |
2006-10-20 |
삼성에스디아이 주식회사 |
발광 표시 장치
|
US6703359B1
(en)
*
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
EP1056774A1
(de)
*
|
1998-02-27 |
2000-12-06 |
Novo Nordisk A/S |
N-terminal verkürzte glp-1 derivate
|
EP1932535A3
(de)
|
1998-07-31 |
2008-10-29 |
Novo Nordisk A/S |
Anregung der Beta-Zellbildung
|
US6720407B1
(en)
*
|
1998-08-28 |
2004-04-13 |
Eli Lilly And Company |
Method for administering insulinotropic peptides
|
US6429197B1
(en)
|
1998-10-08 |
2002-08-06 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
|
US7259136B2
(en)
*
|
1999-04-30 |
2007-08-21 |
Amylin Pharmaceuticals, Inc. |
Compositions and methods for treating peripheral vascular disease
|
EP2322545A1
(de)
|
1998-12-07 |
2011-05-18 |
Ipsen Pharma |
GLP-1 Analoge
|
US7258869B1
(en)
|
1999-02-08 |
2007-08-21 |
Alza Corporation |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
|
US7919109B2
(en)
|
1999-02-08 |
2011-04-05 |
Intarcia Therapeutics, Inc. |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
|
JP4732590B2
(ja)
|
1999-03-15 |
2011-07-27 |
ノボ ノルディスク アクティーゼルスカブ |
Glp−1及び近縁ペプチドのイオン交換クロマトグラフィー分離
|
US6444788B1
(en)
|
1999-03-15 |
2002-09-03 |
Novo Nordisk A/S |
Ion exchange chromatography of GLP-1, analogs and derivatives thereof
|
US6451987B1
(en)
|
1999-03-15 |
2002-09-17 |
Novo Nordisk A/S |
Ion exchange chromatography of proteins and peptides
|
US6605648B1
(en)
*
|
1999-04-06 |
2003-08-12 |
Phillips Plastics Corporation |
Sinterable structures and method
|
US6514500B1
(en)
*
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
US20090175821A1
(en)
*
|
1999-05-17 |
2009-07-09 |
Bridon Dominique P |
Modified therapeutic peptides with extended half-lives in vivo
|
SI1180121T1
(en)
|
1999-05-17 |
2004-04-30 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
US9006175B2
(en)
*
|
1999-06-29 |
2015-04-14 |
Mannkind Corporation |
Potentiation of glucose elimination
|
PT1808438E
(pt)
|
1999-06-29 |
2015-01-14 |
Mannkind Corp |
Purificação e estabilização de péptidos e proteínas em agentes farmacêuticos
|
US6844321B2
(en)
|
2000-01-31 |
2005-01-18 |
Novo Nordisk A/S |
Crystallization of a GLP-1 analogue
|
EP1634605A3
(de)
|
2000-03-08 |
2006-10-11 |
Novo Nordisk A/S |
Behandlung von Dyslipämie bei einem Patienten mit Typ 2 Diabetes
|
CA2405912A1
(en)
|
2000-04-12 |
2001-10-18 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP1346722B1
(de)
|
2000-12-01 |
2008-12-10 |
Takeda Pharmaceutical Company Limited |
Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
|
WO2002085406A1
(en)
*
|
2001-04-24 |
2002-10-31 |
Restoragen, Inc. |
Methods and compositions for treating conditions associated with insulin resistance
|
EP2022505B1
(de)
*
|
2001-07-31 |
2011-12-14 |
The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services |
GLP-1, Exendin-4, Peptid-Analoga und Verwendungen davon
|
US6642003B2
(en)
|
2001-08-02 |
2003-11-04 |
Cedars-Sinai Medical Center |
Human glucose-dependent insulin-secreting cell line
|
ES2545090T3
(es)
|
2001-12-21 |
2015-09-08 |
Human Genome Sciences, Inc. |
Proteínas de fusión de albúmina y GCSF
|
AU2002364587A1
(en)
*
|
2001-12-21 |
2003-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
WO2005003296A2
(en)
|
2003-01-22 |
2005-01-13 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7141240B2
(en)
*
|
2002-03-12 |
2006-11-28 |
Cedars-Sinai Medical Center |
Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
|
WO2003080149A2
(en)
|
2002-03-20 |
2003-10-02 |
Mannkind Corporation |
Inhalation apparatus
|
US20080260838A1
(en)
*
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
US7790681B2
(en)
*
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
US20040209803A1
(en)
*
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
JP4565193B2
(ja)
|
2003-04-23 |
2010-10-20 |
バレリタス, インコーポレイテッド |
長い持続時間の医薬投与のための液圧作動式ポンプ
|
ES2425221T3
(es)
*
|
2003-05-30 |
2013-10-14 |
Amylin Pharmaceuticals, Llc |
Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
|
JP5622998B2
(ja)
|
2003-08-21 |
2014-11-12 |
ノヴォ ノルディスク アー/エス |
ラセミ化されたアミノ酸を含むポリペプチドの分離
|
EP1663289A2
(de)
*
|
2003-08-29 |
2006-06-07 |
Amylin Pharmaceuticals, Inc. |
Verfahren zur behandlung oder linderung von erkrankungen und störungen im zusammenhang mit ghrelin
|
MXPA06005581A
(es)
|
2003-11-20 |
2006-08-11 |
Novo Nordisk As |
Formulaciones de peptidos que contienen propilenglicol que son optimas para la produccion y uso en dispositivos de inyeccion.
|
JP4865565B2
(ja)
|
2003-12-09 |
2012-02-01 |
ノヴォ ノルディスク アー/エス |
Glp−1アゴニストを用いた食物選択の制御
|
US20080194483A1
(en)
*
|
2003-12-12 |
2008-08-14 |
Brownlee Michael A |
GLP-1 (9-36) methods and compositions
|
CA2550217A1
(en)
*
|
2003-12-12 |
2005-07-07 |
Michael A. Brownlee |
Glp-1 (9-36) methods and compositions
|
TWI353250B
(en)
|
2003-12-16 |
2011-12-01 |
Ipsen Pharma Sas |
Glp-1 pharmaceutical compositions
|
EP2210900A3
(de)
|
2003-12-16 |
2010-08-11 |
Ipsen Pharma |
GlLP-1-Analoga
|
AU2005211725B2
(en)
*
|
2004-02-09 |
2010-07-15 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
BRPI0510117A
(pt)
*
|
2004-04-23 |
2007-09-25 |
Conjuchem Biotechnologies Inc |
método para purificação de conjugados de albumina
|
US20090069226A1
(en)
*
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
EP1758575A1
(de)
|
2004-06-11 |
2007-03-07 |
Novo Nordisk A/S |
Bekämpfung von arzneimittel-induzierter fettleibigkeit unter verwendung von glp-1-agonisten
|
US9089636B2
(en)
|
2004-07-02 |
2015-07-28 |
Valeritas, Inc. |
Methods and devices for delivering GLP-1 and uses thereof
|
JP5078014B2
(ja)
|
2004-08-20 |
2012-11-21 |
マンカインド コーポレイション |
ジケトピペラジン合成の触媒反応
|
HUE026797T2
(en)
|
2004-08-23 |
2016-07-28 |
Mannkind Corp |
Diceto-piperazine salts for drug delivery
|
DE102004043153B4
(de)
*
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
KR20120060245A
(ko)
|
2005-09-14 |
2012-06-11 |
맨카인드 코포레이션 |
활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
|
US8039432B2
(en)
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
WO2007064757A1
(en)
*
|
2005-11-29 |
2007-06-07 |
University Of Florida Research Foundation, Inc. |
Anti-thymocyte globulin to prevent or delay the onset or the progression on type 1 diabetes
|
WO2007075534A2
(en)
|
2005-12-16 |
2007-07-05 |
Nektar Therapeutics Al, Corporation |
Polymer conjugates of glp-1
|
ES2364982T3
(es)
*
|
2006-02-08 |
2011-09-20 |
Lonza Ag |
Síntesis de péptidos similares a glucagón.
|
EP2497484A3
(de)
|
2006-02-22 |
2012-11-07 |
MannKind Corporation |
Verfahren zur Verbesserung der pharmazeutischen Eigenschaften von Mikropartikeln mit Diketopiperazin und einem Wirkstoff
|
EP2005309B1
(de)
|
2006-03-30 |
2016-02-17 |
Valeritas, Inc. |
Flüssigkeitsausgabevorrichtung mit mehreren kartuschen
|
JP5143131B2
(ja)
|
2006-05-30 |
2013-02-13 |
インターシア セラピューティクス,インコーポレイティド |
浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
|
PL2359808T3
(pl)
|
2006-08-09 |
2013-10-31 |
Intarcia Therapeutics Inc |
Osmotyczne systemy dostawcze i zespoły tłokowe
|
MX2009011123A
(es)
*
|
2007-04-23 |
2009-11-02 |
Intarcia Therapeutics Inc |
Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
|
EP2581441A1
(de)
|
2007-08-09 |
2013-04-17 |
Genzyme Corporation |
Verfahren zur Behandlung von Autoimmunerkrankungen mit mesenchymalen Stammzellen
|
WO2009046015A2
(en)
*
|
2007-09-30 |
2009-04-09 |
University Of Florida Research Foundation, Inc. |
Combination therapies for treating type 1 diabetes
|
WO2009055740A2
(en)
*
|
2007-10-24 |
2009-04-30 |
Mannkind Corporation |
Method of preventing adverse effects by glp-1
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
KR20100090692A
(ko)
*
|
2007-10-24 |
2010-08-16 |
맨카인드 코포레이션 |
활성제의 전달
|
CA2708762A1
(en)
*
|
2007-12-11 |
2009-06-18 |
Conjuchem Biotechnologies Inc. |
Formulation of insulinotropic peptide conjugates
|
EP2240155B1
(de)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
|
EP3281663B8
(de)
|
2008-06-13 |
2022-09-21 |
MannKind Corporation |
Atemluftbetriebener trockenpulverinhalator zur verabreichung von medikamenten
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
US9364619B2
(en)
|
2008-06-20 |
2016-06-14 |
Mannkind Corporation |
Interactive apparatus and method for real-time profiling of inhalation efforts
|
TWI494123B
(zh)
|
2008-08-11 |
2015-08-01 |
Mannkind Corp |
超快起作用胰島素之用途
|
EP2344519B1
(de)
*
|
2008-11-07 |
2016-09-28 |
The General Hospital Corporation |
C-terminale fragmente von glucagon-ähnlichem peptid-1 (glp-1)
|
CN102271775A
(zh)
|
2008-12-08 |
2011-12-07 |
诺沃-诺迪斯克有限公司 |
多肽的逆流提纯
|
US8314106B2
(en)
|
2008-12-29 |
2012-11-20 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
CA2754595C
(en)
|
2009-03-11 |
2017-06-27 |
Mannkind Corporation |
Apparatus, system and method for measuring resistance of an inhaler
|
WO2010144789A2
(en)
|
2009-06-12 |
2010-12-16 |
Mannkind Corporation |
Diketopiperazine microparticles with defined specific surface areas
|
NZ598686A
(en)
|
2009-09-28 |
2014-05-30 |
Intarcia Therapeutics Inc |
Rapid establishment and/or termination of substantial steady-state drug delivery
|
CA2778698A1
(en)
|
2009-11-03 |
2011-05-12 |
Mannkind Corporation |
An apparatus and method for simulating inhalation efforts
|
CA2782056C
(en)
|
2009-11-25 |
2021-03-09 |
Arisgen Sa |
Mucosal delivery of peptides
|
EP2555791B1
(de)
|
2010-04-09 |
2017-11-01 |
Sinai Health System |
Verfahren zur behandlung von erkrankungen des magen-darm-trakts mittels eines glp-1-agonisten
|
US9782454B2
(en)
|
2010-04-22 |
2017-10-10 |
Longevity Biotech, Inc. |
Highly active polypeptides and methods of making and using the same
|
AU2011271097B2
(en)
|
2010-06-21 |
2014-11-27 |
Mannkind Corporation |
Dry powder drug delivery system and methods
|
BR112012033295A2
(pt)
|
2010-07-02 |
2016-10-11 |
Angiochem Inc |
polipeptídeos curtos e contendo d-aminoácido para conjugados terapêuticos e seu uso
|
WO2012054861A1
(en)
|
2010-10-22 |
2012-04-26 |
Nektar Therapeutics |
Glp-1 polymer conjugates having a releasable linkage
|
WO2012054822A1
(en)
|
2010-10-22 |
2012-04-26 |
Nektar Therapeutics |
Pharmacologically active polymer-glp-1 conjugates
|
WO2012061466A2
(en)
|
2010-11-02 |
2012-05-10 |
The General Hospital Corporation |
Methods for treating steatotic disease
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
CN105667994B
(zh)
|
2011-04-01 |
2018-04-06 |
曼金德公司 |
用于药物药盒的泡罩包装
|
WO2012174472A1
(en)
|
2011-06-17 |
2012-12-20 |
Mannkind Corporation |
High capacity diketopiperazine microparticles
|
EP2729157B1
(de)
|
2011-07-06 |
2019-01-16 |
The General Hospital Corporation |
Ein pentapeptid aus dem c-terminus des glucagon-like peptids-1 (glp-1) zur verwendung in der behandlung
|
KR20140095483A
(ko)
|
2011-10-24 |
2014-08-01 |
맨카인드 코포레이션 |
통증을 치료하기 위한 방법 및 조성물
|
AR091476A1
(es)
|
2012-06-21 |
2015-02-04 |
Univ Indiana Res & Tech Corp |
POLIPEPTIDOS DE FUSION DE REGION Fc DE POLIPEPTIDO DE LIGANDO RECEPTOR DE INCRETINA Y CONJUGADOS CON FUNCION EFECTORA Fc ALTERADA
|
US20150157619A1
(en)
|
2012-07-10 |
2015-06-11 |
Takeda Pharmaceutical Company Limited |
Pharmaceutical preparation for injection
|
DK2872205T3
(en)
|
2012-07-12 |
2017-02-27 |
Mannkind Corp |
DRY POWDER FORMAL ADMINISTRATION SYSTEM
|
WO2014066856A1
(en)
|
2012-10-26 |
2014-05-01 |
Mannkind Corporation |
Inhalable influenza vaccine compositions and methods
|
KR102499439B1
(ko)
|
2013-03-15 |
2023-02-13 |
맨카인드 코포레이션 |
미세결정성 디케토피페라진 조성물 및 방법
|
US9789164B2
(en)
|
2013-03-15 |
2017-10-17 |
Longevity Biotech, Inc. |
Peptides comprising non-natural amino acids and methods of making and using the same
|
WO2015010092A1
(en)
|
2013-07-18 |
2015-01-22 |
Mannkind Corporation |
Heat-stable dry powder pharmaceutical compositions and methods
|
JP2016530930A
(ja)
|
2013-08-05 |
2016-10-06 |
マンカインド コーポレイション |
通気装置及び方法
|
CN106029087A
(zh)
|
2013-12-20 |
2016-10-12 |
印第安纳大学研究及科技有限公司 |
脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽
|
WO2015148905A1
(en)
|
2014-03-28 |
2015-10-01 |
Mannkind Corporation |
Use of ultrarapid acting insulin
|
CN104267194B
(zh)
*
|
2014-09-23 |
2016-01-13 |
上海市东方医院 |
人胰高血糖素样肽-1、抗体及其试剂盒
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
US10561806B2
(en)
|
2014-10-02 |
2020-02-18 |
Mannkind Corporation |
Mouthpiece cover for an inhaler
|
AU2016270984B2
(en)
|
2015-06-03 |
2021-02-25 |
Intarcia Therapeutics, Inc. |
Implant placement and removal systems
|
CN109310743A
(zh)
|
2016-05-16 |
2019-02-05 |
因塔西亚制药公司 |
胰高血糖素受体选择性多肽及其使用方法
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
EP3565580B1
(de)
|
2017-01-03 |
2024-03-06 |
i2o Therapeutics, Inc. |
Kontinuierlicher verabreichung von exenatid und co-verabreichung von acetaminophen, ethinylestradiol oder levonorgestrel
|
TWI783890B
(zh)
|
2017-08-24 |
2022-11-11 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1組成物及其用途
|
AU2019357621A1
(en)
|
2018-10-11 |
2021-05-27 |
Intarcia Therapeutics, Inc. |
Human amylin analog polypeptides and methods of use
|
KR20220143037A
(ko)
|
2020-02-18 |
2022-10-24 |
노보 노르디스크 에이/에스 |
Glp-1 조성물 및 이의 용도
|
CA3223596A1
(en)
*
|
2021-06-29 |
2023-01-05 |
Thomas A. GILL |
Peptides for regulating glucose
|